The historical rank and industry rank for Kintara Therapeutics's Equity-to-Asset or its related term are showing as below:
KTRA'
s Equity-to-Asset Range Over the Past 10 Years
Min: -1.37 Med: 0.73 Max: 0.89
Current: -0.09
During the past 13 years, the highest Equity to Asset Ratio of Kintara Therapeutics was 0.89. The lowest was -1.37. And the median was 0.73.
KTRA's Equity-to-Asset is ranked worse than 85.35% of 1563
companies
in the Biotechnology industry
Industry Median: 0.66
vs KTRA: -0.09
Kintara Therapeutics Equity-to-Asset Historical Data
The historical data trend for Kintara Therapeutics's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Kintara Therapeutics's Equity-to-Asset
For the Biotechnology subindustry, Kintara Therapeutics's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Kintara Therapeutics's Equity-to-Asset Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Kintara Therapeutics's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where Kintara Therapeutics's Equity-to-Asset falls into.
Kintara Therapeutics Equity-to-Asset Calculation
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
Kintara Therapeutics's Equity to Asset Ratio for the fiscal year that ended in Jun. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
Kintara Therapeutics Equity-to-Asset Related Terms
Thank you for viewing the detailed overview of Kintara Therapeutics's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.
Kintara Therapeutics (Kintara Therapeutics) Business Description
Kintara Therapeutics Inc is engaged in the development of novel cancer therapies for patients with unmet medical needs. The company is developing two late-stage, Phase 3-ready therapeutics for clear unmet medical needs with reduced risk development programs. The two programs are VAL-083 for GBM and REM-001 for CMBC. VAL-083 is a small-molecule chemotherapeutic with a novel mechanism of action that has demonstrated clinical activity against a range of cancers, including the central nervous system, ovarian, and other solid tumors. The company operates within a single operating segment the research and development of cancer indications, and operates primarily in one geographic area, being North America.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
KTRA has been successfully added to your 